Modification of accessory molecule signaling

Springer Seminars in Immunopathology

Volumn 27, Issue 4, 2006, Pages 409-424

  Crow, Mary K ^a  

^a HOSPITAL FOR SPECIAL SURGERY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELL ADHESION MOLECULE; TOLL LIKE RECEPTOR;

ACCESSORY CELL; ANTIGEN EXPRESSION; ANTIGEN PRESENTING CELL; AUTOIMMUNE DISEASE; AUTOIMMUNITY; CELL INTERACTION; DENDRITIC CELL; GENETIC POLYMORPHISM; HUMAN; IMMUNE RESPONSE; IMMUNE SYSTEM; INNATE IMMUNITY; KNOCKOUT MOUSE; MEDIATOR RELEASE; NONHUMAN; PRIORITY JOURNAL; REVIEW; RHEUMATIC DISEASE; SIGNAL TRANSDUCTION; T LYMPHOCYTE ACTIVATION; TARGET CELL;

ANIMALS; ANTIGENS, CD28; ANTIGENS, CD80; ANTIGENS, CD86; CD40 LIGAND; HUMANS; LYMPHOCYTE ACTIVATION; MICE; SIGNAL TRANSDUCTION; T-LYMPHOCYTES;

EID: 33744726259     PISSN: 03444325     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00281-006-0018-3     Document Type: Review

References (81)

1. Beutler B (2005) The Toll-like receptors: analysis by forward genetic methods. Immunogenetics 57: 385-392
2. Ronnblom L, Eloranta ML, Alm GV (2006) The type I interferon system in systemic lupus erythematosus. Arthritis Rheum 54:408-420
3. Crow MK, Kirou KA (2004) Interferon-alpha in systemic lupus erythematosus. Curr Opin Rheumatol 16:541-547
4. Edelman GM (1987) CAMs and Igs: cell adhesion and the evolutionary origins of immunity. Immunol Rev 100:11-45
5. Coyle AJ, Gutierrez-Ramos JC (2001) The expanding B7 superfamily: increasing complexity in costimulatory signals regulating T cell function. Nat Immunol 2:203-209
6. Frauwirth KA, Thompson CB (2002) Activation and inhibition of lymphocytes by costimulation. J Clin Invest 109:295-299
7. Gonzalo JA, Delaney T, Corcoran J, Goodearl A, Gutierrez-Ramos JC, Coyle AJ (2001) Cutting edge: the related molecules CD28 and inducible costimulator deliver both unique and complementary signals required for optimal T cell activation. J Immunol 166:1-5
8. Peggs KS, Allison JP (2005) Co-stimulatory pathways in lymphocyte regulation: the immunoglobulin superfamily. Br J Haematol 130:809-824
9. Sharpe AH, Freeman GJ (2002) The B7-CD28 superfamily. Nat Rev Immunol 2:116-126
10. Shapiro L, Scherer PE (1998) The crystal structure of a complement-1q family protein suggests an evolutionary link to tumor necrosis factor. Curr Biol 8:335-338
11. Banchereau J, Bazan F, Blanchard D, Briere F, Galizzi JP, van Kooten C, Liu YJ, Rousset F, Saeland S (1994) The CD40 antigen and its ligand. Annu Rev Immunol 12:881-922
12. Bretscher P, Cohn M (1970) A theory of self-nonself discrimination. Science 169:1042-1049
13. Bretscher P (1992) The two-signal model of lymphocyte activation twenty-one years later. Immunol Today 13:74-76
14. Crow MK, Kunkel HG (1982) Human dendritic cells: major stimulators of the autologous and allogeneic mixed leucocyte reactions. Clin Exp Immunol 49:338-346
15. van Voorhis WC, Valinsky J, Hoffman E, Luban J, Hair LS, Steinman RM (1983) Relative efficacy of human monocytes and dendritic cells as accessory cells for T cell replication. J Exp Med 158:174-191
16. Crow MK, Kunkel HG (1985) Activated B lymphocytes: stimulators of an augmented autologous mixed leukocyte reaction. Cell Immunol 90:555-568
17. Schwartz RH (2003) T cell anergy. Annu Rev Immunol 21:305-334
18. Beyersdorf N, Gaupp S, Balbach K, Schmidt J, Toyka KV, Lin CH, Hanke T, Hunig T, Kerkau T, Gold R (2005) Selective targeting of regulatory T cells with CD28 superagonists allows effective therapy of experimental autoimmune encephalomyelitis. J Exp Med 202:445-455
19. Beyersdorf N, Hanke T, Kerkau T, Hunig T (2006) CD28 superagonists put a break on autoimmunity by preferentially activating CD4+CD25+ regulatory T cells. Autoimmun Rev 5:40-45
20. Dabbagh K, Dahl ME, Stepick-Biek P, Lewis DB (2002) Toll-like receptor 4 is required for optimal development of Th2 immune responses: role of dendritic cells. J Immunol 168:4524-4530
21. Shlomchik MJ, Craft JE, Mamula MJ (2001) From T to B and back again: positive feedback in systemic autoimmune disease. Nat Rev Immunol 1:147-153
22. Martens PB, Goronzy JJ, Schaid D, Weyand CM (1997) Expansion of unusual CD4+ T cells in severe rheumatoid arthritis. Arthritis Rheum 40:1106-1114
23. Coyle AJ, Lehar S, Lloyd C, Tian J, Delaney T, Manning S, Nguyen T, Burwell T, Schneider H, Gonzalo JA, Gosselin M, Owen LR, Rudd CE, Gutierrez-Ramos JC (2000) The CD28-related molecule ICOS is required for effective T cell-dependent immune responses. Immunity 13:95-105
24. Hutloff A, Dittrich AM, Beier KC, Eljaschewitsch B, Kraft R, Anagnostopoulos I, Kroczek RA (1999) ICOS is an inducible T-cell co-stimulator structurally and functionally related to CD28. Nature 397: 263-266
25. Okazaki T, Iwai Y, Honjo T (2002) New regulatory co-receptors: inducible co-stimulator and PD-1. Curr Opin Immunol 14:779-782
26. Wallin JJ, Liang L, Bakardjiev A, Sha WC (2001) Enhancement of CD8+ T cell responses by ICOS/B7h costimulation. J Immunol 167:132-139
27. Futagawa T, Akiba H, Kodama T, Takeda K, Hosoda Y, Yagita H, Okumura K (2002) Expression and function of 4-1BB and 4-1BB ligand on murine dendritic cells. Int Immunol 14:275-286
28. Linton PJ, Bautista B, Biederman E, Bradley ES, Harbertson J, Kondrack RM, Padrick RC, Bradley LM (2003) Costimulation via OX40L expressed by B cells is sufficient to determine the extent of primary CD4 cell expansion and Th2 cytokine secretion in vivo. J Exp Med 197:875-883
29. Lindstein T, June CH, Ledbetter JA, Stella G, Thompson CB (1989) Regulation of lymphokine messenger RNA stability by a surface-mediated T cell activation pathway. Science 244:339-343
30. de Boer M, Kasran A, Kwekkeboom J, Walter H, Vandenberghe P, Ceuppens JL (1993) Ligation of B7 with CD28/CTLA-4 on T cells results in CD40 ligand expression, interleukin-4 secretion and efficient help for antibody production by B cells. Eur J Immunol 23:3120-3125
31. Smith KM, Brewer JM, Webb P, Coyle AJ, Gutierrez-Ramos C, Garside P (2003) Inducible costimulatory molecule-B7-related protein 1 interactions are important for the clonal expansion and B cell helper functions of naive, Th1, and Th2 T cells. J Immunol 170:2310-2315
32. Freeman GJ, Long AJ, Iwai Y, Bourque K, Chernova T, Nishimura H, Fitz LJ, Malenkovich N, Okazaki T, Byrne MC, Horton HF, Fouser L, Carter L, Ling V, Bowman MR, Carreno BM, Collins M, Wood CR, Honjo T (2000) Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med 192:1027-1034
33. Greenwald RJ, Latchman YE, Sharpe AH (2002) Negative co-receptors on lymphocytes. Curr Opin Immunol 14:391-396
34. Greenwald RJ, Oosterwegel MA, van der Woude D, Kubal A, Mandelbrot DA, Boussiotis VA, Sharpe AH (2002) CTLA-4 regulates cell cycle progression during a primary immune response. Eur J Immunol 32:366-373
35. Riley JL, June CH (2005) The CD28 family: a T-cell rheostat for therapeutic control of T-cell activation. Blood 105:13-21
36. Collins AV, Brodie DW, Gilbert RJ, Iaboni A, Manso-Sancho R, Walse B, Stuart DI, van der Merwe PA, Davis SJ (2002) The interaction properties of costimulatory molecules revisited. Immunity 17:201-210
37. McAdam AJ, Greenwald RJ, Levin MA, Chernova T, Malenkovich N, Ling V, Freeman GJ, Sharpe AH (2001) ICOS is critical for CD40-mediated antibody class switching. Nature 409:102-105
38. Liszewski MK, Farries TC, Lublin DM, Rooney IA, Atkinson JP (1996) Control of the complement system. Adv Immunol 61:201-283
39. Mackay F, Kalled SL (2002) TNF ligands and receptors in autoimmunity: an update. Curr Opin Immunol 14:783-790
40. Allen RC, Armitage RJ, Conley ME, Rosenblatt H, Jenkins NA, Copeland NG, Bedell MA, Edelhoff S, Disteche CM, Simoneaux DK et al (1993) CD40 ligand gene defects responsible for X-linked hyper-IgM syndrome. Science 259:990-993
41. Lederman S, Yellin MJ, Krichevsky A, Belko J, Lee JJ, Chess L (1992) Identification of a novel surface protein on activated CD4+ T cells that induces contact-dependent B cell differentiation (help). J Exp Med 175:1091-1101
42. Klaus SJ, Pinchuk LM, Ochs HD, Law CL, Fanslow WC, Armitage RJ, Clark EA (1994) Costimulation through CD28 enhances T cell-dependent B cell activation via CD40-CD40L interaction. J Immunol 152:5643-5652
43. Lederman S, Yellin MJ, Cleary AM, Pernis A, Inghirami G, Cohn LE, Covey LR, Lee JJ, Rothman P, Chess L (1994) T-BAM/CD40-L on helper T lymphocytes augments lymphokine-induced B cell Ig isotype switch recombination and rescues B cells from programmed cell death. J Immunol 152: 2163-2171
44. Shapira SK, Vercelli D, Jabara HH, Fu SM, Geha RS (1992) Molecular analysis of the induction of immunoglobulin E synthesis in human B cells by interleukin 4 and engagement of CD40 antigen. J Exp Med 175:289-292
45. Splawski JB, Fu SM, Lipsky PE (1993) Immunoregulatory role of CD40 in human B cell differentiation. J Immunol 150:1276-1285
46. Schattner EJ, Elkon KB, Yoo DH, Tumang J, Krammer PH, Crow MK, Friedman SM (1995) CD40 ligation induces Apo-1/Fas expression on human B lymphocytes and facilitates apoptosis through the Apo-1/Fas pathway. J Exp Med 182:1557-1565
47. Caux C, Massacrier C, Vanbervliet B, Dubois B, van Kooten C, Durand I, Banchereau J (1994) Activation of human dendritic cells through CD40 cross-linking. J Exp Med 180:1263-1272
48. Alderson MR, Armitage RJ, Tough TW, Strockbine L, Fanslow WC, Spriggs MK (1993) CD40 expression by human monocytes: regulation by cytokines and activation of monocytes by the ligand for CD40. J Exp Med 178:669-674
49. Kobayashi N, Nagumo H, Agematsu K (2002) IL-10 enhances B-cell IgE synthesis by promoting differentiation into plasma cells, a process that is inhibited by CD27/CD70 interaction. Clin Exp Immunol 129:446-452
50. Kumar-Sinha C, Varambally S, Sreekumar A, Chinnaiyan AM (2002) Molecular cross-talk between the TRAIL and interferon signaling pathways. J Biol Chem 277:575-585
51. Cerutti A, Schaffer A, Goodwin RG, Shah S, Zan H, Ely S, Casali P (2000) Engagement of CD153 (CD30 ligand) by CD30+ T cells inhibits class switch DNA recombination and antibody production in human IgD+ IgM+ B cells. J Immunol 165:786-794
52. Pollard KM, Hultman P, Kono DH (2003) Using single-gene deletions to identify checkpoints in the progression of systemic autoimmunity. Ann N YAcad Sci 987:236-239
53. Castigli E, Alt FW, Davidson L, Bottaro A, Mizoguchi E, Bhan AK, Geha RS (1994) CD40-deficient mice generated by recombination-activating gene-2-deficient blastocyst complementation. Proc Natl Acad Sci USA 91:12135-12139
54. Dong C, Juedes AE, Temann UA, Shresta S, Allison JP, Ruddle NH, Flavell RA (2001) ICOS costimulatory receptor is essential for T-cell activation and function. Nature 409:97-101
55. Tivol EA, Borriello F, Schweitzer AN, Lynch WP, Bluestone JA, Sharpe AH (1995) Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity 3:541-547
56. Waterhouse P, Penninger JM, Timms E, Wakeham A, Shahinian A, Lee KP, Thompson CB, Griesser H, Mak TW (1995) Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4. Science 270:985-988
57. Nishimura H, Nose M, Hiai H, Minato N, Honjo T (1999) Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. Immunity 11:141-151
58. Chu JL, Drappa J, Parnassa A, Elkon KB (1993) The defect in Fas mRNA expression in MRL/lpr mice is associated with insertion of the retrotransposon, ETn. J Exp Med 178:723-730
59. Hudson LL, Rocca K, Song YW, Pandey JP (2002) CTLA-4 gene polymorphisms in systemic lupus erythematosus: a highly significant association with a determinant in the promoter region. Hum Genet 111:452-455
60. Desai-Mehta A, Lu L, Ramsey-Goldman R, Datta SK (1996) Hyperexpression of CD40 ligand by B and T cells in human lupus and its role in pathogenic autoantibody production. J Clin Invest 97:2063-2073
61. Koshy M, Berger D, Crow MK (1996) Increased expression of CD40 ligand on systemic lupus erythematosus lymphocytes. J Clin Invest 98:826-837
62. Mohan C, Shi Y, Laman JD, Datta SK (1995) Interaction between CD40 and its ligand gp39 in the development of murine lupus nephritis. J Immunol 154:1470-1480
63. Vakkalanka RK, Woo C, Kirou KA, Koshy M, Berger D, Crow MK (1999) Elevated levels and functional capacity of soluble CD40 ligand in systemic lupus erythematosus sera. Arthritis Rheum 42:871-881
64. Kato K, Santana-Sahagun E, Rassenti LZ, Weisman MH, Tamura N, Kobayashi S, Hashimoto H, Kipps TJ (1999) The soluble CD40 ligand sCD154 in systemic lupus erythematosus. J Clin Invest 104:947-955
65. Bijl M, Horst G, Limburg PC, Kallenberg CG (2001) Expression of costimulatory molecules on peripheral blood lymphocytes of patients with systemic lupus erythematosus. Ann Rheum Dis 60: 523-526
66. Prokunina L, Castillejo-Lopez C, Oberg F, Gunnarsson I, Berg L, Magnusson V, Brookes AJ, Tentler D, Kristjansdottir H, Grondal G, Bolstad AI, Svenungsson E, Lundberg I, Sturfelt G, Jonssen A, Truedsson L, Lima G, Alcocer-Varela J, Jonsson R, Gyllensten UB, Harley JB, Alarcon-Segovia D, Steinsson K, Alarcon-Riquelme ME (2002) A regulatory polymorphism in PDCD1 is associated with susceptibility to systemic lupus erythematosus in humans. Nat Genet 32:666-669
67. Pullmann R Jr, Lukac J, Skerenova M, Rovensky J, Hybenova J, Melus V, Celec S, Pullmann R, Hyrdel R (1999) Cytotoxic T lymphocyte antigen 4 (CTLA-4) dimorphism in patients with systemic lupus erythematosus. Clin Exp Rheumatol 17:725-729
68. Abrams JR, Kelley SL, Hayes E, Kikuchi T, Brown MJ, Kang S, Lebwohl MG, Guzzo CA, Jegasothy BV, Linsley PS, Krueger JG (2000) Blockade of T lymphocyte costimulation with cytotoxic T lymphocyte-associated antigen 4-immunoglobulin (CTLA4Ig) reverses the cellular pathology of psoriatic plaques, including the activation of keratinocytes, dendritic cells, and endothelial cells. J Exp Med 192:681-694
69. Daikh DI, Finck BK, Linsley PS, Hollenbaugh D, Wofsy D (1997) Long-term inhibition of murine lupus by brief simultaneous blockade of the B7/CD28 and CD40/gp39 costimulation pathways. J Immunol 159:3104-3108
70. Emery P (2003) The therapeutic potential of costimulatory blockade with CTLA4Ig in rheumatoid arthritis. Expert Opin Investig Drugs 12:673-681
71. Bluestone JA, St Clair EW, Turka LA (2006) CTLA4Ig: Bridging the basic immunology with clinical application. Immunity 24:233-238
72. Moreland LW, Alten R, van den Bosch F, Appelboom T, Leon M, Emery P, Cohen S, Luggen M, Shergy W, Nuamah I, Becker JC (2002) Costimulatory blockade in patients with rheumatoid arthritis: a pilot, dose-finding, double-blind, placebo-controlled clinical trial evaluating CTLA-4Ig and LEA29Y eighty-five days after the first infusion. Arthritis Rheum 46:1470-1479
73. Knoerzer DB, Karr RW, Schwartz BD, Mengle-Gaw LJ (1995) Collagen-induced arthritis in the BB rat. Prevention of disease by treatment with CTLA-4-Ig. J Clin Invest 96:987-993
74. Wang X, Huang W, Mihara M, Sinha J, Davidson A (2002) Mechanism of action of combined short-term CTLA4Ig and anti-CD40 ligand in murine systemic lupus erythematosus. J Immunol 168:2046-2053
75. Tiede I, Fritz G, Strand S, Poppe D, Dvorsky R, Strand D, Lehr HA, Wirtz S, Becker C, Atreya R, Mudter J, Hildner K, Bartsch B, Holtmann M, Blumberg R, Walczak H, Iven H, Galle PR, Ahmadian MR, Neurath MF (2003) CD28-dependent Rac1 activation is the molecular target of azathioprine in primary human CD4+ T lymphocytes. J Clin Invest 111:1133-1145
76. Kosuge H, Suzuki J, Gotoh R, Koga N, Ito H, Isobe M, Inobe M, Uede T (2003) Induction of immunologic tolerance to cardiac allograft by simultaneous blockade of inducible co-stimulator and cytotoxic T-lymphocyte antigen 4 pathway. Transplantation 75:1374-1379
77. Foell J, Strahotin S, O'Neil SP, McCausland MM, Suwyn C, Haber M, Chander PN, Bapat AS, Yan XJ, Chiorazzi N, Hoffmann MK, Mittler RS (2003) CD137 costimulatory T cell receptor engagement reverses acute disease in lupus-prone NZB x NZW F1 mice. J Clin Invest 111:1505-1518
78. Kalled SL, Cutler AH, Datta SK, Thomas DW (1998) Anti-CD40 ligand antibody treatment of SNF1 mice with established nephritis: preservation of kidney function. J Immunol 160:2158-2165
79. Kalunian KC, Davis JC Jr, Merrill JT, Totoritis MC, Wofsy D (2002) Treatment of systemic lupus erythematosus by inhibition of T cell costimulation with anti-CD154: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 46:3251-3258
80. Huang W, Sinha J, Newman J, Reddy B, Budhai L, Furie R, Vaishnaw A, Davidson A (2002) The effect of anti-CD40 ligand antibody on B cells in human systemic lupus erythematosus. Arthritis Rheum 46:1554-1562
81. Peggs KS, Quezada SA, Korman AJ, Allison JP (2006) Principles and use of anti-CTLA4 antibody in human cancer immunotherapy. Curr Opin Immunol 18:206-213